JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial [...] Read more »
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
JERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company"), a leader in the development of orally delivered peptides and small therapeutic proteins, [...] Read more »
Lifezone Metals Announces Publication of H1 2023 Financial Results and Shareholder Letter
New York (United States), Sept. 20, 2023 (GLOBE NEWSWIRE) — Lifezone Metals Limited ("Lifezone Metals" or the "Company") (NYSE: LZM), a modern metals company creating value across the battery metals supply chain [...] Read more »
[INVNT GROUP]™ achieves record global growth, accelerating history-making brand campaigns, strategic partnerships, and humanitarian work.
New York, NY, May 11, 2023 (GLOBE NEWSWIRE) — [INVNT GROUP] THE GLOBAL BRANDSTORY PROJECT and leading agency portfolio of complementary brand storytelling disciplines, continues its explosive growth trajectory and worldwide [...] Read more »
Cellebrite Announces First-Quarter 2023 Results
Revenue of $71.2 million, 14% year–over–year increase due primarily to
27% growth in subscription revenue;
ARR of $261.3 million, up 30% [...] Read more »
Entera Bio Announces Q1 2023 Financial Results and Corporate Updates
JERUSALEM, May 05, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today [...] Read more »
Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022
JERUSALEM, March 31, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today [...] Read more »
Cellebrite Announces Fourth Quarter 2022 Results
ARR of $249 million, up 33% year–over–year
Fourth–quarter revenue of $74.0 million, [...] Read more »
Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today [...] Read more »
Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022
JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today [...] Read more »
Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization
Risk of symptomatic COVID–19 was reduced by 71% compared to placebo in pre–exposure prophylaxis and 75% compared to placebo in post–exposure prophylaxis
Risk of [...] Read more »
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results
FDA Feedback Supports Planned Emergency Use Authorization (EUA) Submission for ADG20 for Prevention of COVID–19; Interim Clinical Data Package from EVADE Prevention Trial to Support EUA Submission Expected in Second [...] Read more »
Bombardier reports its third quarter 2021 results, demonstrates solid execution and strong cash flow performance
- Business aircraft revenues of $1.4 billion, up 17% year–over–year, mainly driven by an improved delivery mix and continued strong aftermarket recovery as overall fleet flight hours surpass 2019 [...] Read more »
Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021 Financial Results
New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID–19 to be Presented at IDWeek 2021
Patient Population in Global EVADE Phase 2/3 Clinical [...] Read more »
CORRECTION – Zoom Reports Financial Results for the Second Quarter of Fiscal Year 2022
- Second quarter total revenue of $1,021.5 million, up 54% year over year
- Number of customers [...] Read more »